循环肿瘤细胞 z-bo 2020-10-26 400

　　Recently, Dai Haimin and Nijinfu's research team from the Institute of Health and Medical Technology of the Kawagoe Institute of Materials Science, Chinese Academy of Sciences have made new progress in the enrichment and detection of circulating tumor cells (CTC). The research results were published in "Biotechnology Letters." CTC is a general term for various types of tumor cells present in peripheral blood. The spontaneous or diagnostic and therapeutic procedures caused by solid tumor lesions (primary tumors, metastases) cause most CTCs to enter the peripheral blood, causing cell apoptosis or swallowing.

　　Some will escape and repair, develop metastasis and increase malignant tumors. The risk of death for cancer patients. Compared with traditional tissue biopsy, CTC detection has the following advantages: easy operation, less trauma, less patient pain, and higher repeatability. Compared with a single tissue site, it can dynamically reflect the patient's disease process and treatment status in real time. Biopsy can provide more comprehensive information. However, because the peripheral blood lacks carbon tetrachloride, there is only one carbon tetrachloride in about 107 white blood cells per milliliter of blood, making it heterogeneous and easy to aggregate. Masking can also interfere with the separation and molecular identification of CTC. , Limiting the clinical application of carbon tetrachloride detection. In recent years, researchers have developed a series of enrichment and detection technologies and methods based on the physical, chemical and biological properties of carbon tetrachloride.

　　However, currently only the FDA has approved the CellSearch system for metastatic breast, prostate and metastatic breast cancer. The detection of colorectal cancer has become a standard experimental protocol. Due to the high detection miss rate and the limitation of not being able to capture live cells, it is necessary to develop a new CTC detection method. Based on the CellSearch system, the research team designed a CTC capture method based on CD45/CD326 target-based immunomagnetic bead enrichment and flow cytometry detection. After the negative enrichment of CD45 immunomagnetic beads and the positive enrichment of CD326, the proportion of blood CTC that could not be detected in the test blood increased to more than 24.14%. Since this method does not involve the destruction of cell membrane integrity, the carbon tetrachloride obtained by the researchers has cell activity, which can be used for cell reculture and further analysis, as well as clinical diagnosis and personalized treatment.

　　This research was supported by the National Natural Science Foundation of China, the Medical Physics Technology Center of Kawagoe Research Institute and Anhui Medical University.